Study of Rifaximin in Minimal Hepatic Encephalopathy
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease, Neurology, Psychiatric |
| Therapuetic Areas: | Immunology / Infectious Diseases, Neurology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | February 2010 |
| End Date: | September 2012 |
| Contact: | Jasmohan S Bajaj, MD |
| Email: | jsbajaj@vcu.edu, jasmohan.bajaj@va.gov |
| Phone: | 804 675 5802 |
Effect of Rifaximin Therapy on Brain Activation in Patients With Minimal Hepatic Encephalopathy Using Functional MR, MR Spectroscopy and Diffusion Tensor Imaging: a Prospective Trial
Rifaximin therapy will improve brain functioning on MRI scanning.
Inclusion Criteria:
- Age 18-65 years
- cirrhosis diagnosed by clinical or biopsy grounds
- Minimal hepatic encephalopathy defined by impaired performance on at least 2 of the
following: number connection tests A/B, digit symbol and block design tests (NCT-A,
NCT-B, DST and BDT) compared to age and education-matched controls.
- No contraindications to MRI
- TIPS (transjugular intra-hepatic porto-systemic shunt) procedure or elective surgery
planned within the next 8 weeks
Exclusion Criteria:
- Current therapy with lactulose, rifaximin or other treatment for hepatic
encephalopathy.
- Prior episodes of overt HE
- MMSE <25
- TIPS placement
- Unable to give informed consent.
- Contra-indications to MRI
We found this trial at
1
site
Click here to add this to my saved trials
